Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of paclitaxel plus rivoceranib in high P-glycoprotein–expressing GIST after multiple TKIs
KCT0008554Phase 2Recruiting
- Sponsor
- HLB Cell
- Start
- Sep 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, Rivoceranib in gastrointestinal stromal tumor (GIST), sponsored by HLB Cell. Started Sep 2023; status: recruiting.
02
Drugs
paclitaxelRivoceranib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on KCT0008554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008554.